P2X and P2Y receptor antagonists reduce inflammation in ATP-induced microglia.

IF 2.4 Q3 PHARMACOLOGY & PHARMACY
Pharmacy Practice-Granada Pub Date : 2023-01-01 Epub Date: 2022-01-05 DOI:10.18549/PharmPract.2023.1.2788
Amer Imraish, Tuqa Abu-Thiab, Hana Hammad
{"title":"P<sub>2</sub>X and P2Y receptor antagonists reduce inflammation in ATP-induced microglia.","authors":"Amer Imraish,&nbsp;Tuqa Abu-Thiab,&nbsp;Hana Hammad","doi":"10.18549/PharmPract.2023.1.2788","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>P2 receptors have been implicated in the release of neurotransmitter and pro-inflammatory cytokines due to their response to neuro-excitatory substances in the microglia. The P2X4, P2X7 and P2Y12 receptors are involved in the development of pain behavior induced by peripheral nerve injury. However, it is not known if blocking P2X4, P2X7 and P2Y12 receptors is associated with the expression and the release of interleukin-1B (IL-1β), interleukin-6 (IL-6), or tumor necrosis factor-α (TNF-α) in cultured neonatal spinal cord microglia.</p><p><strong>Objective: </strong>For this reason, we examined the effects of P2X4, P2X7 and P2Y12 antagonists on the expression and the release of IL-1β, IL-6, and TNF-α in ATP-stimulated microglia.</p><p><strong>Methods: </strong>In this study, we observed the effect of A-740003, PSB-12062 and MRS 2395 (P2X4, P2X7 and P2Y12 receptors antagonist, respectively), on the expression and release of IL-1β, IL-6 and TNF-α by using real-time fluorescence quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>ATP induced the increased expression of IL-1β, IL-6 and TNF-α at the level of messenger RNA (mRNA). ATP-evoked increase in IL-1β, IL-6 and TNF-α mRNA expression was inhibited by the P2X4 receptor antagonist A-740003 or P2X7 receptor antagonist PSB-12062, respectively. Similarly, ATP-evoked release of IL-1β, IL-6 and TNF-α was inhibited by A-740003 and PSB-12062. Furthermore, ATP-evoked increased expression of Iba-1, IL-1β, IL-6 and TNF-α mRNA, and release of IL-1β, IL-6 and TNF-α were nearly all blocked after co-administration of A-740003 plus PSB-12062. Finally, ATP-evoked increased gene expression and release of IL-1β, IL-6 and TNF-α were also inhibited by MRS 2395 (P2Y12 antagonist).</p><p><strong>Conclusion: </strong>These observations suggest a new clue for therapeutic strategies to treat the neuro-inflammation.</p>","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"21 1","pages":"2788"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/f5/pharmpract-21-2788.PMC10117305.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Practice-Granada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18549/PharmPract.2023.1.2788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: P2 receptors have been implicated in the release of neurotransmitter and pro-inflammatory cytokines due to their response to neuro-excitatory substances in the microglia. The P2X4, P2X7 and P2Y12 receptors are involved in the development of pain behavior induced by peripheral nerve injury. However, it is not known if blocking P2X4, P2X7 and P2Y12 receptors is associated with the expression and the release of interleukin-1B (IL-1β), interleukin-6 (IL-6), or tumor necrosis factor-α (TNF-α) in cultured neonatal spinal cord microglia.

Objective: For this reason, we examined the effects of P2X4, P2X7 and P2Y12 antagonists on the expression and the release of IL-1β, IL-6, and TNF-α in ATP-stimulated microglia.

Methods: In this study, we observed the effect of A-740003, PSB-12062 and MRS 2395 (P2X4, P2X7 and P2Y12 receptors antagonist, respectively), on the expression and release of IL-1β, IL-6 and TNF-α by using real-time fluorescence quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).

Results: ATP induced the increased expression of IL-1β, IL-6 and TNF-α at the level of messenger RNA (mRNA). ATP-evoked increase in IL-1β, IL-6 and TNF-α mRNA expression was inhibited by the P2X4 receptor antagonist A-740003 or P2X7 receptor antagonist PSB-12062, respectively. Similarly, ATP-evoked release of IL-1β, IL-6 and TNF-α was inhibited by A-740003 and PSB-12062. Furthermore, ATP-evoked increased expression of Iba-1, IL-1β, IL-6 and TNF-α mRNA, and release of IL-1β, IL-6 and TNF-α were nearly all blocked after co-administration of A-740003 plus PSB-12062. Finally, ATP-evoked increased gene expression and release of IL-1β, IL-6 and TNF-α were also inhibited by MRS 2395 (P2Y12 antagonist).

Conclusion: These observations suggest a new clue for therapeutic strategies to treat the neuro-inflammation.

Abstract Image

Abstract Image

Abstract Image

P2X和P2Y受体拮抗剂减少ATP诱导的小胶质细胞的炎症。
背景:P2受体与神经递质和促炎细胞因子的释放有关,因为它们对小胶质细胞中的神经兴奋性物质有反应。P2X4、P2X7和P2Y12受体参与由外周神经损伤诱导的疼痛行为的发展。然而,尚不清楚阻断P2X4、P2X7和P2Y12受体是否与培养的新生儿脊髓小胶质细胞中白细胞介素1B(IL-1β)、白细胞介蛋白-6(IL-6)或肿瘤坏死因子-α(TNF-α)的表达和释放有关。目的:为此,我们研究了P2X4、P2X7和P2Y12拮抗剂对ATP刺激的小胶质细胞中IL-1β、IL-6和TNF-α表达和释放的影响。方法:采用实时荧光定量聚合酶链反应(PCR)和酶联免疫吸附试验(ELISA)观察A-740003、PSB-12062和MRS 2395(分别为P2X4、P2X7和P2Y12受体拮抗剂)对IL-1β、IL-6和TNF-α表达和释放的影响,IL-6和TNF-。P2X4受体拮抗剂A-740003或P2X7受体拮抗物PSB-12062分别抑制ATP诱导的IL-1β、IL-6和TNF-αmRNA表达的增加。类似地,ATP诱导的IL-1β、IL-6和TNF-α的释放被A-740003和PSB-12062抑制。此外,ATP诱导的Iba-1、IL-1β、IL-6和TNF-αmRNA的表达增加,以及IL-1β,IL-6和TNF--α的释放在A-740003和PSB-12062联合给药后几乎全部被阻断。最后,ATP引起的IL-1β、IL-6和TNF-α基因表达和释放的增加也被MRS 2395(P2Y12拮抗剂)抑制。结论:这些观察结果为治疗神经炎症的策略提供了新的线索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacy Practice-Granada
Pharmacy Practice-Granada PHARMACOLOGY & PHARMACY-
CiteScore
3.90
自引率
4.00%
发文量
113
审稿时长
20 weeks
期刊介绍: Pharmacy Practice is a free full-text peer-reviewed journal with a scope on pharmacy practice. Pharmacy Practice is published quarterly. Pharmacy Practice does not charge and will never charge any publication fee or article processing charge (APC) to the authors. The current and future absence of any article processing charges (APCs) is signed in the MoU with the Center for Pharmacy Practice Innovation (CPPI) at Virginia Commonwealth University (VCU) School of Pharmacy. Pharmacy Practice is the consequence of the efforts of a number of colleagues from different Universities who belief in collaborative publishing: no one pays, no one receives. Although focusing on the practice of pharmacy, Pharmacy Practice covers a wide range of pharmacy activities, among them and not being comprehensive, clinical pharmacy, pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信